{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:20:32Z","timestamp":1760833232805,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.nmd.2021.09.003","type":"journal-article","created":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T05:56:31Z","timestamp":1633758991000},"page":"801-802","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tamoxifen in Duchenne muscular dystrophy \u2013 promising first results"],"prefix":"10.1016","volume":"31","author":[{"given":"Urs","family":"R\u00fcegg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2021.09.003_bib0001","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","article-title":"Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals","volume":"50","author":"Koenig","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.nmd.2021.09.003_bib0002","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1172\/JCI115244","article-title":"Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dystrophin gene of Duchenne muscular dystrophy kobe","volume":"87","author":"Matsuo","year":"1991","journal-title":"J Clin Investig"},{"key":"10.1016\/j.nmd.2021.09.003_bib0003","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3390\/jcm10040820","article-title":"Innovative therapeutic approaches for Duchenne muscular dystrophy","volume":"10","author":"Fortunato","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.nmd.2021.09.003_bib0004","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ajpath.2012.10.018","article-title":"The anticancer drug tamoxifen counteracts the pathology in a mouse model of Duchenne muscular dystrophy","volume":"182","author":"Dorchies","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nmd.2021.09.003_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2021.05.005","article-title":"Safety and clinical outcome of tamoxifen in Duchenne Muscular Dystrophy","author":"Tsabari","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.09.003_bib0006","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jpeds.2004.03.057","article-title":"Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia","volume":"145","author":"Lawrence","year":"2004","journal-title":"J Pediatr"},{"key":"10.1016\/j.nmd.2021.09.003_bib0007","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1542\/peds.2005-0577","article-title":"The use of tamoxifen to improve height potential in short pubertal boys","volume":"116","author":"Kreher","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.nmd.2021.09.003_bib0008","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1515\/JPEM.2008.21.5.449","article-title":"Long-term follow-up of tamoxifen treatment in adolescents with gynecomastia","volume":"21","author":"Derman","year":"2008","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.nmd.2021.09.003_bib0009","unstructured":"Wells, D. personal communication."},{"key":"10.1016\/j.nmd.2021.09.003_bib0010","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1186\/s13063-019-3740-6","article-title":"Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial","volume":"20","author":"Nagy","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.nmd.2021.09.003_bib0011","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/1574884711308020006","article-title":"The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice","volume":"8","author":"Maximov","year":"2013","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.nmd.2021.09.003_bib0012","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1038\/s41467-018-07058-4","article-title":"Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy","volume":"9","author":"Gayi","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.nmd.2021.09.003_bib0013","first-page":"4848","article-title":"Tamoxifen therapy of myotubular myopathy","volume":"19","author":"Maani","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.nmd.2021.09.003_bib0014","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ajpath.2017.12.011","article-title":"Long-term treatment of tamoxifen and raloxifene alleviates dystrophic phenotype and enhances muscle functions of FKRP dystroglycanopathy","volume":"188","author":"Wu","year":"2018","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nmd.2021.09.003_bib0015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1152\/physrev.00007.2015","article-title":"Absence of dystrophin disrupts skeletal muscle signaling: Roles of Ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy","volume":"96","author":"Allen","year":"2016","journal-title":"Physiol Rev"},{"key":"10.1016\/j.nmd.2021.09.003_bib0016","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/hmg\/ddn408","article-title":"Dominant-negative inhibition of Ca2+ influx via TRPV2 ameliorates muscular dystrophy in animal models","volume":"18","author":"Iwata","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2021.09.003_bib0017","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/cdd.2015.65","article-title":"Genetic evidence in the mouse solidifies the calcium hypothesis of myofiber death in muscular dystrophy","volume":"22","author":"Burr","year":"2015","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.nmd.2021.09.003_bib0018","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/clpt.2011.27","article-title":"Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma","volume":"89","author":"M\u00fcrdter","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nmd.2021.09.003_bib0019","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1476-5381.1996.tb15445.x","article-title":"Regulation of cytosolic calcium in skeletal muscle cells of the mdx mouse under conditions of stress","volume":"118","author":"Leijendekker","year":"1996","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.nmd.2021.09.003_bib0020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/21678707.2018.1452733","article-title":"The potential and benefits of repurposing existing drugs to treat rare muscular dystrophies","volume":"6","author":"Ismail","year":"2018","journal-title":"Expert Opinion Orphan Drugs"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621006246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621006246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:10:45Z","timestamp":1760775045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896621006246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0960896621006246"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2021.09.003","relation":{},"ISSN":["0960-8966"],"issn-type":[{"type":"print","value":"0960-8966"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tamoxifen in Duchenne muscular dystrophy \u2013 promising first results","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2021.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}